ReviewGut2022
Cross-roads for meta-analysis and network meta-analysis of
Review in Gut, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- The association between periodontal diseases and helicobacter pylori: an updated meta-analysis of observational studies.BMC oral health · 2023Pooled it
- Novel MAXPOWER biological antibacterial liquid for eradicating oral Helicobacter pylori.BMC infectious diseases · 2024Trial
- Clinical utility of fecal Sanger sequencing and PCR alongside gastric biopsy E-test forMicrobiology spectrum · 2026Article
- Hydrogel-Transformable Probiotic Powder for Targeted Eradication of Helicobacter pylori with Enhanced Gastric Mucosal Repair and Microbiota Preservation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Therapeutic regimens againstTherapeutic advances in gastroenterology · 2025Article
- Overcoming the effects of increasing antimicrobial resistance onExpert review of gastroenterology & hepatology · 2024Review
- Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies forAntibiotics (Basel, Switzerland) · 2024Article
- Crises in Antimicrobial Stewardship: Misuse of Clarithromycin forPharmacoepidemiology · 2024Article
- H. Pylori Treatment in the COVID-19 Era. What Have We Learned So Far?Current gastroenterology reports · 2024Review
- Best Practices forGastroenterology & hepatology · 2024Article
- The causal relationship between trace element status and upper gastrointestinal ulcers: a Mendelian randomization study.Frontiers in nutrition · 2024Article
- Article
- Newer, Older, and Alternative Agents for the Eradication ofAntibiotics (Basel, Switzerland) · 2023Review
- Standard Bismuth Quadruple Therapy versus Concomitant Therapy for the First-Line Treatment ofJournal of clinical medicine · 2023Review
- [Approach to Patients with ConsecutiveThe Korean journal of helicobacter and upper gastrointestinal research · 2023Review
- A Simplified Low-Dose 10-Day Quadruple Therapy with a Galenic Formulation of Bismuth Salicylate Is Highly Effective forJournal of clinical medicine · 2023Article
- Implications of the paradigm shift in management ofTherapeutic advances in gastroenterology · 2023Review
- How widespread and convenientExpert review of gastroenterology & hepatology · 2023Review
- The status quo of short videos as a health information source ofFrontiers in public health · 2023Article
- Comparative effectiveness of first-line therapies for eradication of antibiotic-resistantWorld journal of clinical cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.